21 CFR Part 211 · Current Good Manufacturing Practice for Finished Pharmaceuticals

21 CFR 211.125

Labeling issuance

21 CFR 211.125 is the regulation titled “Labeling issuance” in 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals. Since 2021, 4 FDA warning letters have cited it.

Letters citing it
4 since 2021
Jan 1 to Oct 30, 2026
1 against 1 on the same dates in 2025
Most often cited with
21 CFR 211.22, in 4 letters
Closed out
0% of these letters have a published close-out
See the 4 letters citing 21 CFR 211.125 →

Letters citing it, by year issued

All are drug letters. 2026 runs to Oct 30, 2026. Pick a year to see its letters.

  1. 02021
  2. 02022
  3. 02023
  4. 12024
  5. 22025
  6. 12026

What FDA writes when it cites it

The finding headings that cite 21 CFR 211.125 most often, as written in the letters.

  • 2 lettersYour firm failed to exercise strict control over labeling issued for use in drug product labeling operations (21 CFR 211.125(a))
  • 1 letterYour firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d))
  • 1 letterYour firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188)

The regulation

Read the text of 21 CFR 211.125 (eCFR, as of Sep 1, 2026)

(a) Strict control shall be exercised over labeling issued for use in drug product labeling operations.

(b) Labeling materials issued for a batch shall be carefully examined for identity and conformity to the labeling specified in the master or batch production records.

(c) Procedures shall be used to reconcile the quantities of labeling issued, used, and returned, and shall require evaluation of discrepancies found between the quantity of drug product finished and the quantity of labeling issued when such discrepancies are outside narrow preset limits based on historical operating data. Such discrepancies shall be investigated in accordance with § 211.192. Labeling reconciliation is waived for cut or roll labeling if a 100-percent examination for correct labeling is performed in accordance with § 211.122(g)(2).

(d) All excess labeling bearing lot or control numbers shall be destroyed.

(e) Returned labeling shall be maintained and stored in a manner to prevent mixups and provide proper identification.

(f) Procedures shall be written describing in sufficient detail the control procedures employed for the issuance of labeling; such written procedures shall be followed.

[43 FR 45077, Sept. 29, 1978, as amended at 58 FR 41354, Aug. 3, 1993; 81 FR 81697, Nov. 18, 2016; 89 FR 51769, June 18, 2024]

Text from eCFR as of Sep 1, 2026.

Cited alongside it

Regulations that appear in the same letters as 21 CFR 211.125.

Latest letters citing it

The 3 letters citing 21 CFR 211.125 that FDA posted most recently.

See the 4 letters citing 21 CFR 211.125 →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Counts include every citation in a letter, as the Letters filter does. How this database is built.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.